MIAMI, April 30, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc., (Nasdaq:NRXP or "the Company"), today announced the grant of a filing fee waiver by the US Food and Drug Administration ("FDA") to ...
Waiver exempts NRx from paying a $4.3 million New Drug Application filing fee under the Prescription Drug User Fee Act (PDUFA) Company is on track for Q2 2025 completion of NDA filing and PDUFA date ...
Waiver exempts NRx from paying a $4.3 million New Drug Application filing fee under the Prescription Drug User Fee Act (PDUFA) Company is on track for Q2 2025 completion of NDA filing and PDUFA date ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback